辽宁成大：新一届管理层推动公司轻装前行，强化主业聚焦与科技赋能

Core Viewpoint - Liaoning Chengda Co., Ltd. has decided to permanently suspend operations at Xinjiang Baoming Mining Co., Ltd. and will not make further large cash investments, focusing instead on introducing strategic investors to address funding and development issues [1] Group 1: Management Changes - The company held its first temporary shareholders' meeting in 2025, where the board of directors was re-elected, and Xu Biao was elected as the chairman [1] - Xu Biao has extensive experience and familiarity with the company, having served on the board since 2020 and currently holding positions in Guangdong Minying Investment Co., Ltd. [1] - Zhang Shanwei, the new president, has a background in industrial investment and management, contributing to the company's strategic direction [2] Group 2: Strategic Focus and Collaborations - The new management team is promoting a culture of achievement and openness, aiming for a shift towards innovative development and technology [2] - Liaoning Chengda's subsidiary, Chengda Bio, has signed a cooperation agreement with Zhongke Zhidong Taichu to establish an "AI + Vaccine Research Joint Laboratory" [2] - A strategic cooperation agreement was also signed with the Institute of Microbiology of the Chinese Academy of Sciences, focusing on emerging infectious diseases [2][3] Group 3: Financial Strategies and Debt Management - The company is optimizing its debt structure and enhancing its financing capabilities, which has led to a reduction in financing costs [3] - In 2025, the company issued short-term financing bonds totaling 14 billion yuan, with decreasing interest rates [3] - The company plans to issue exchangeable bonds to improve resource allocation and strengthen its core competitiveness [4]